Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase NA 6Phase 1/2 4Phase 3 3Phase 2 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 9Unknown 8Recruiting 6Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 7Carcinoma, Hepatocellular 6Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Rectal Neoplasms 4Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Hematologic Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acute Kidney Injury 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1

Interventions

fludarabine 1Whole-Body Irradiation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Leukemia × Clear all
NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Actinium Pharmaceuticals

Phase 2/3 Not yet recruiting
306 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡